advertisement

Topcon

Saeedi OJ 25

Showing records 1 to 25 | Display all abstracts from Saeedi OJ

84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Tracey BM
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Wang M
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Mayo LN
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Tichelaar J; Pasquale LR
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Le CT
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Shen LQ
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Chen VY; Weichsel J
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Boland MV; Wellik SR
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Renner CY; Li J
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
De Moraes CG
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Tsai JJ
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Myers JS
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Kalarn SP
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Ramulu P; Kwon M
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Ou MT
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Saeedi OJ
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Chang LY
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Wang H
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Mohammed TK
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Baniasadi N
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Mohammed ISK; Shah KA
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Li D; Bex PJ
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Thompson GM; Jones AMK
Scientific reports 2019; 9: 20178
84857 Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence
Elze T
JAMA ophthalmology 2020; 0:
84825 Measurement of Retinal Microvascular Blood Velocity Using Erythrocyte Mediated Velocimetry
Im LT; Kaleem MA; Saeedi OJ
Scientific reports 2019; 9: 20178

Issue 21-1

Change Issue


advertisement

Oculus